> Table 48: Combined modality treatment and overall survival in inflammatory breast cancer
This summary table contains detailed information about research studies. While viewing summary tables offers an informative glimpse at the science behind many breast cancer guidelines and recommendations, they should be viewed with some caution. There are a number of concepts you must understand to be able to successfully read and interpret research tables. To get some background information about understanding research tables, please see How to Read a Research Table.
|
Introduction: Inflammatory breast cancer is a rare but severe form of breast cancer. In the past, with surgery and/or radiation therapy, only a small percentage of women with inflammatory breast cancer lived longer than five years. However, new standard treatment regimens use combinations of therapies and have greatly improved survival rates. These regimens—often called combined-modality treatment—use chemotherapy, radiation therapy and surgery in a variety of orders. Five-year overall survival rates for inflammatory breast cancer now range from about 30 to 70 percent with combined modality treatment (see studies below).
Study selection criteria: Clinical trials with 50 or more participants on combined modality therapy with at least five years follow-up.
| |
Study
|
Study Population (number of participants)
|
Treatments Studied
|
5-year Overall Survival Rate
|
Clinical Trials
|
Palangie et al. [1]
|
223
|
Chemotherapy>>radiation therapy>>chemotherapy with or without immunotherapy with or without hormone therapy with or without mastectomy
|
41%
|
Ueno et al. [2]
|
178
|
Chemotherapy>>radiation therapy>>chemotherapy
OR
Chemotherapy>>mastectomy>>chemotherapy>>radiation therapy
|
40%
|
Chevallier et al. [3]
|
178
|
Chemotherapy>>radiation therapy with or without mastectomy with or without chemotherapy
|
32%
|
Attia-Sobol et al. [4]
|
103
|
Chemotherapy>>radiation therapy>>chemotherapy
OR
Chemotherapy with or without radiation therapy with or without surgery with or without radiation therapy>>chemotherapy
|
55%
|
Perez et al. [5]
|
86
|
Radiation therapy>>mastectomy>>chemotherapy
|
38%*†
|
Harris et al. [6]
|
54
|
Chemotherapy>>radiation therapy with or without mastectomy>>chemotherapy
OR
Chemotherapy>>mastectomy>>radiation therapy>>chemotherapy
OR
Mastectomy>>chemotherapy>>radiation therapy>>chemotherapy
|
56%
|
* Estimate from figure in original article.
† Breast cancer survival rather than overall survival.
References
1. Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 7:921-7, 1994.
2. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 40:321-9, 1997.
3. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non-metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer. 67:594-601, 1993.
4. Attia-Sobol JA, Ferriere J, Cure H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer. 29A:1081-1088, 1993.
5. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory Carcinoma. Cancer. 74:466-76, 1994.
6. Harris EER, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J. Radiation Oncology Biol Phys. 55:1200-1208, 2003.
Updated 09/12/09
